Sensitive Determination of 20(S)-Protopanaxadiol in Rat Plasma Using HPLC–APCI-MS: Application of Pharmacokinetic Study in Rats
Hong-can Ren,Jian-guo Sun,Guang-ji Wang,Ji-ye A,Hai-tang Xie,Wei-bin Zha,Bei Yan,Fen-zhi Sun,Hai-ping Hao,Sheng-hua Gu,Long-sheng Sheng,Feng Shao,Jian Shi,Fang Zhou
DOI: https://doi.org/10.1016/j.jpba.2008.09.045
IF: 3.571
2008-01-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:20(S)-Protopanaxadiol (PPD), the main metabolite of protopanoxadiol type ginsenosides (e.g. Rg3 and Rh2), is a very promising anti-cancer drug candidate. To evaluate the pharmacokinetic property of PPD, we reported a reliable, sensitive and simple method utilizing liquid chromatography (HPLC)-atmospheric pressure chemical ionization-mass spectrometry (APCI-MS) to determine PPD. PPD and the internal standard, panoxadiol (PD) were extracted from plasma with acetic ether, separated on a C18 reverse column, and then analyzed by APCI-MS. Targeting fragment ion at m/z 425 for both PPD and PD was monitored in selected-ion monitoring (SIM) mode. PPD can be quantitatively determined at the concentration as low as 1ng/mL using 200μL plasma. And the sensitive method showed excellent linearity over a range from 1 to 1000ng/mL, high recovery, accuracy and precision at the concentrations of 2.5, 100.0 and 1000.0ng/mL, respectively. The method was successfully applied to pharmacokinetic study of PPD in rats. Pharmacokinetic parameters were calculated and absolute bioavailability of PPD was 36.8±12.4%, at least ten times higher than that of Rg3 and Rh2, indicating its good absorption in gastrointestinal tract. It was further suggested that PPD be a promising anti-cancer candidate and probably responsible for the observed pharmacological activity of Rg3 and Rh2.